Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.
Cook J, Gonsalves WI, Gertz MA, Visram A, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Kapoor P, Kourelis TV, Hayman SR, Kyle RA, Muchtar E, Kumar SK, Hogan WJ, Jacob EK, Buadi FK. Cook J, et al. Among authors: jacob ek. Bone Marrow Transplant. 2022 Jun;57(6):1007-1009. doi: 10.1038/s41409-022-01659-w. Epub 2022 Apr 2. Bone Marrow Transplant. 2022. PMID: 35368041 No abstract available.
Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.
Al Saleh AS, Sidiqi MH, Lee J, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Skaer CA, Wittwer SK, Wolf RC, Hogan WJ, Kumar SK, Jacob E, Gertz MA. Al Saleh AS, et al. Bone Marrow Transplant. 2020 Nov;55(11):2132-2137. doi: 10.1038/s41409-020-0916-3. Epub 2020 May 1. Bone Marrow Transplant. 2020. PMID: 32358546 Free PMC article.
The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience.
Vaxman I, Muchtar E, Jacob E, Kapoor P, Kumar S, Dispenzieri A, Buadi F, Dingli D, Gonsalves W, Kourelis T, Warsame R, Lacy M, Hogan W, Gertz MA. Vaxman I, et al. Transplant Cell Ther. 2021 Sep;27(9):770.e1-770.e7. doi: 10.1016/j.jtct.2021.06.016. Epub 2021 Jun 18. Transplant Cell Ther. 2021. PMID: 34153504 Free PMC article.
Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions.
Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, Litzow MR, Hashmi SK, Yadav H, Iyer VN, Scott JP, Wylam ME, Cartin-Ceba R, Patnaik MM. Hefazi M, et al. Among authors: jacob ek. Biol Blood Marrow Transplant. 2018 Sep;24(9):1906-1913. doi: 10.1016/j.bbmt.2018.04.012. Epub 2018 Apr 18. Biol Blood Marrow Transplant. 2018. PMID: 29679771 Free article.
High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia.
Ravindran A, Sankaran J, Jacob EK, Kreuter JD, Hook CC, Gertz MA, Call TG, Pruthi RK, Litzow MR, Wolanskyj AP, Hogan WJ, Ashrani AA, Begna KH, Marshall AL, Kyle RA, Kay NE, Go RS. Ravindran A, et al. Among authors: jacob ek. Am J Hematol. 2017 Aug;92(8):E164-E166. doi: 10.1002/ajh.24765. Epub 2017 Jun 1. Am J Hematol. 2017. PMID: 28437873 Free article. No abstract available.
ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
Hefazi M, Litzow M, Hogan W, Gastineau D, Jacob E, Damlaj M, Hashmi S, Al-Kali A, Patnaik MM. Hefazi M, et al. Transfusion. 2016 Feb;56(2):518-27. doi: 10.1111/trf.13353. Epub 2015 Oct 7. Transfusion. 2016. PMID: 26446051 Clinical Trial.
60 results